semaglutide peptide therapy History of glucagon-like peptide-1 receptor agonists Weight Loss Peptide Therapy in

GLP-1 receptor agonists reduce energy intake by up to roughly 40%, according to a 2025 review of the evidence, and they do it through three overlapping pathways: appetite suppression, delayed gastric emptying, and altered nutrient absorption

Interested in the underlying studies and trial summaries

The most common reactions include transient digestive upset (nausea, vomiting, stomach cramps, or diarrhea), a mild fishy body odor, headache, or soreness and redness where the injection is given

Prioritising high-quality proteins like these also helps to preserve muscle during weight loss

If you have medullary thyroid cancer or genetic testing that puts you at risk for thyroid cancer, or you have a family member who has medullary thyroid cancer, they say you shouldn't use these drugs

Tesamorelin is not indicated for weight loss management (weight neutral effect)